Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer

Inclusion Criteria:

Women diagnosed with breast cancer stages I-III initiating first line adjuvant aromatase inhibitor (AI) therapy with any of the FDA-approved AIs (anastrazole, exemestane, letrozole)
Concurrent gonadotropin-releasing hormone (GnRH) agonist therapy is allowed; concurrent breast related radiation therapy is allowed.
Prior tamoxifen use is allowed
Prior chemotherapy is allowed
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Metastatic malignancy of any kind
Rheumatoid arthritis and other types of autoimmune and inflammatory joint disease
AI use > 21 days prior to study enrollment
Known bleeding disorders
Current use of warfarin or other anticoagulants
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements
Daily use of n-3 PUFA concentrates or capsules or any other supplements that might interact with n-3 PUFA supplements if > 375 mg per day of of eicosapentaenoic acid (EPA)/ docosahexaenoic acid (DHA) within six months of study initiation
Pregnant or nursing women
Known sensitivity or allergy to fish or fish oil
Unable to give informed consent